Advertisement

Frontiers of Medicine in China

, Volume 4, Issue 1, pp 8–15 | Cite as

Using sound Clinical Paths and Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia therapy

  • Zhi-Ruo Zhang
  • Jian-Qing Mi
  • Long-Jun Gu
  • Jing-Yan Tang
  • Shu-Hong Shen
  • Zhao-Jun Wen
  • Sai-Juan Chen
  • Zhu ChenEmail author
Health Policy Forum

Abstract

China has been undertaking a profound reform on health care. Although more than 1.16 billion people have been covered by rural and urban medical insurance to date, the level of reimbursement from insurance is very limited, especially for critical diseases such as leukemia. This places heavy economic burdens on patients. Under these circumstances, systems innovation is imperative for the efficient utilization of limited funding. In this respect, certain valuable experience from other countries may prove helpful. The prospective payment system of Diagnosis-related Groups (DRGs), Clinical Paths, and the Comparative Effectiveness Analysis adopted by the National Institute of Health and Clinical Excellence (NICE, UK), can be fine tools to reduce medical costs and improve quality of services. Treatments of acute promyelocytic leukemia at Rui-Jin Hospital, and childhood acute lymphoblastic leukemia at Shanghai Children’s Medical Center, can be taken as suitable models to illustrate the crucial role of Clinical Paths in guaranteeing clinical and cost effectiveness of medical services for critical diseases, and to satisfactorily justify the feasibility of DRGs in China.

Keywords

healthcare reform diagnosis-related groups clinical paths comparative effectiveness analysis acute promyelocytic leukemia childhood acute lymphoblastic leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guidelines for Deepening Health-care Reform. State Council of China. http://news.xinhuanet.com/newscenter/2009-04/07/content_11142999_1.htm (in Chinese)
  2. 2.
    Action Plan for Healthcare Reform in 2009–2011. State Council of China. http://news.xinhuanet.com/newscenter/2009-04/07/content_11142999_1.htm (in Chinese)
  3. 3.
    Announcement issued on the official website of the Ministry of Health of China on Aug. 10, 2009. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohbgt/s6717/200908/42282.htm (in Chinese)
  4. 4.
    News release by the Office of Healthcare Reform Steering Team, State Council of China on Aug. 8, 2009. http://finance.people.com. cn/GB/9815328.html (in Chinese)
  5. 5.
    Chen Z. Launch of the health-care reform plan in China. Lancet, 2009, 373(9672): 1322–1324CrossRefPubMedGoogle Scholar
  6. 6.
    Mayes R. The origins, development, and passage of Medicare’s revolutionary prospective payment system. J Hist Med Allied Sci, 2007, 62(1): 21–55CrossRefPubMedGoogle Scholar
  7. 7.
    Reid B, Sutch S. Comparing diagnosis-related group systems to identify design improvement. Health Policy, 2008, 87(1): 82–91CrossRefPubMedGoogle Scholar
  8. 8.
    Diagnosis Related Groups (DRGs) and the Medicare program: implications for medical technology a technical memorandum. Washington D.C.: US Congress, Office of Technology Assessment, OTA-TM-H-17. 1983Google Scholar
  9. 9.
    Levit K R, Freeland S. National medical care spending. Health Aff, Winter 1988, 124–136Google Scholar
  10. 10.
    Pearson S D, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med, 1995, 123(12): 941–948PubMedGoogle Scholar
  11. 11.
    Audimoolam S, Nair M, Gaikwad R, Qing C. The Role of Clinical Pathways in improving patient outcomes. http://torch.cs.dal.ca/∼asharma/OWL/Role%2520of%2520Clinical%2520Pathways.pdf
  12. 12.
    Weiland D E. Why use clinical pathways rather than practice guidelines? Am J Surg, 1997, 174(6): 592–595CrossRefPubMedGoogle Scholar
  13. 13.
    Rotter T, Kugler J, Koch R, Gothe H, Twork S, van Oostrum J M, Steyerberg E W. A systematic review and meta-analysis of the effects of clinical pathways on length of stay, hospital costs and patient outcomes. BMC Health Serv Res, 2008, 8: 265PubMedGoogle Scholar
  14. 14.
    Rouse A D, Tripp B L, Shipley S, Pories W, Cunningham P, MacDonald K Jr. Meeting the challenge of managed care through clinical pathways for bariatric surgery. Obes Surg, 1998, 8(5): 530–534CrossRefPubMedGoogle Scholar
  15. 15.
    Dowsey M M, Kilgour M L, Santamaria N M, Choong P F. Clinical pathways in hip and knee arthroplasty: a prospective randomised controlled study. Med J Aust, 1999, 170(2): 59–62PubMedGoogle Scholar
  16. 16.
    Birch S, Gafni A. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. Health Econ, 2002, 11(3): 185–191CrossRefPubMedGoogle Scholar
  17. 17.
    Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ, 2001, 323(7324): 1300–1303CrossRefPubMedGoogle Scholar
  18. 18.
    Cheng T M. Medical service quality standards: experiences of the UK’s NICE. Presented at the Conference on Health Reform: Global Healthcare Reform Experiences. 2009Google Scholar
  19. 19.
    Phillips C. What is a QALY? London: Hayward Medical Communications. 2009Google Scholar
  20. 20.
    Wu G H. DRGs’ development and related research in China. Zhongguo Yiyuan Guanli, 2007, 27(7): 10–12 (in Chinese)Google Scholar
  21. 21.
    Announcement of the launching of the pilot program of clinical paths. Bulletin on the Website of the Ministry of Health. Dec. 8, 2009. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3585/200912/44858 (in Chinese)
  22. 22.
    Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Chen Y, Shen Y, Wu W, Tang W, Waxman S, de Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2004, 101(15): 5328–5335.CrossRefPubMedGoogle Scholar
  23. 23.
    Hu J, Liu Y F, Wu CF, Xu F, Shi Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2009, 106(6): 3342–3347CrossRefPubMedGoogle Scholar
  24. 24.
    Liu Y, Chen J, Tang J Y, Ni S X, Xue H L, Pan C. Cost of childhood acute lymphoblastic leukemia care in Shanghai, China. Pediatr Blood Cancer, 2009, 53: 557–562CrossRefPubMedGoogle Scholar

Copyright information

© Higher Education Press and Springer Berlin Heidelberg 2010

Authors and Affiliations

  • Zhi-Ruo Zhang
    • 1
  • Jian-Qing Mi
    • 1
  • Long-Jun Gu
    • 2
  • Jing-Yan Tang
    • 2
  • Shu-Hong Shen
    • 2
  • Zhao-Jun Wen
    • 1
  • Sai-Juan Chen
    • 1
  • Zhu Chen
    • 1
    Email author
  1. 1.Shanghai Institute of HematologyRui-Jin Hospital Affiliated with Shanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Department of Hematology/OncologyShanghai Children’s Medical Center Affiliated with Shanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations